Following our recent patent announcement, the Australian Financial Review has featured Orthocell in its Market Wrap.
The author wrote: “Analysts at Foster Stockbroking like the look of Orthocell, attributing a speculative “buy” recommendation to the stock. The broker sees a number of potential share price catalysts in the short to medium term, in particular, the results of patient studies for the ATI product potentially opening up markets in Japan, Europe and the US.”
Read the article HERE.